Investors Brace for Key Catalysts Across Five Large-Cap Biotech Stocks

A handful of large-cap biotechnology companies are heading toward significant catalysts in the coming weeks, setting the stage for potential stock volatility in a sector that has outperformed the broader market this year. According to a Bank of America note from September 22, 2026, the biotech sector, as measured by the XBI ETF, has gained 22.4% year-to-date, compared to an 11.4% rise in the S&P 500.

Summit Therapeutics Faces Key FDA Decision

Summit Therapeutics (SMMT) faces the most clear-cut binary event with a Prescription Drug User Fee Act (PDUFA) date of November 14, 2026, for its first U.S. regulatory submission. The company also expects a readout from its HARMONi-3 trial in the second half of 2026, according to its second-quarter investor presentation.

The upcoming decision follows positive news on September 3, 2026, when Summit's partner Akeso announced its Phase III HARMONi-2 trial met its overall survival endpoint, causing Summit's stock to rise. However, potential risks include the fact that the trial was conducted exclusively in China and the company's recent establishment of a $380 million at-the-market facility, which could lead to share dilution.

Earnings and Updates to Drive Other Names

For several other firms, upcoming earnings reports and regulatory updates are the primary focus. These events will provide crucial insights into commercial progress and pipeline development.

Ad

• Insmed (INSM): The company anticipates a regulatory decision in Japan for its drug BRINSUPRI in the second half of 2026. With approximately $1.2 billion in cash, Insmed projects it will reach cash-flow positivity in 2027 without needing to raise additional capital, as per its Q2 slides.
• Madrigal Pharmaceuticals (MDGL): The company's third-quarter results on October 29 will be closely watched for momentum in its recent product launch. Consensus estimates project quarterly revenue of about $404 million.
• RevMed (RVMD): As a top pick for Bank of America, expectations are high for this company, which already holds a market capitalization of around $44.1 billion. Its Q3 earnings are scheduled for November 11.
• Arrowhead Pharmaceuticals (ARWR): With its stock having fallen 16.4% in the last three months, the company's November 30 earnings report may attract contrarian interest, though no near-term clinical data releases were noted in the source material.

What This Means for the Market

Biotechnology stock catalysts are inherently high-risk, high-reward events that can result in significant price swings. A positive outcome, such as an FDA approval or strong sales figures, can boost a company's valuation, but there is also a risk that such news is already priced into the stock.

Conversely, a regulatory rejection, clinical trial delay, or weaker-than-expected launch can lead to a sharp decline in share price. Among the companies highlighted, only Summit has a confirmed, near-term regulatory decision date, while the others depend more on quarterly performance and operational updates to drive investor sentiment.